



WHAT'S NEWS

This year is set to be one of significant growth for the EUBREAST Network. We are thrilled to announce our collaboration on the [NAC-AX Delphi Consensus Study](#) and our support for the [PartBreCon-Pro Registry](#) (details below). Additionally, we are pleased to share that we have requested an amendment to extend patient enrollment until December 2027 for the I-PREPARE Study. If you are interested in participating, please be sure to contact us!

Thanks to all of you for your continued support, and a special thought goes out to our colleagues in complicated regions of the world who continue to dedicate themselves tirelessly to this field.

Prof Oreste D Gentilini, Prof Thorsten Kuehn,
and the entire EUBREAST Team

EUBREAST TRIALS: RECRUITING

To learn more about actively recruiting EUBREAST Trials please click on the links below:

[AXSANA Plus / EUBREAST 3 \(R\)](#)
[MELODY / EUBREAST 4 \(R\)](#)
[I-PREPARE / EUBREAST 11 \(R\)](#)
[Neo-ACT / EUBREAST 16 \(R\)](#)



collaborating associations



In Focus: ASCO 2025

EUBREAST was honored to be able to present results on one of the key secondary endpoints of the AXSANA study in the ASCO 2025 Oral Abstract Session: The comparison of different markers placed into the target lymph node before neoadjuvant chemotherapy in patients with node-positive breast cancer. For more information, please attend the related webinar on 28 August 2025 at 18.00.



EUBREAST WEBINARS

We are excited to announce that we will be holding four educational webinars this fall. Please follow us on social media for more info or click here for registration links:

[-Best of Asco for Breast Surgeons](#)
[-EUBREAST Educational Series](#)



THE EUBREAST NETWORK: WEBINARS 2025
SAVE THE DATES
COMPLETE PROGRAM DETAILS AVAILABLE SOON

- 28 AUGUST 2025 - 18.00-19.00 CEST
The Best of ASCO 2025 for Breast Surgeons
- 9 SEPTEMBER 2025 - 18.00-19.00 CEST
De-escalate or Not to De-escalate in Low Nodal Burden After Primary Systemic Therapy: An Interdisciplinary Perspective
- 7 OCTOBER 2025 - 18.00-19.00 CEST
Delving into Targeted Axillary Dissection After Primary Systemic Treatment: From the Oncological Significance to Technical Surgical and Radiological Aspects
- 20 NOVEMBER 2025 - 18.00-19.00 CEST
De-escalate Or Not To De-escalate In High Nodal Burden (cN2-cN3) Converting To yCNO After Primary Systemic Treatment
Free-of-charge, registration will be required

www.eubreast.org

We would like to express our gratitude to our webinar sponsors, whose generosity enables us to share vital scientific information with our community. We are especially grateful for **MSD's** continued support of the Educational Series as Main Sponsor, as well as for the Co-Sponsors of both the Educational Series and Best of ASCO Webinar: **Endomag, Sirius Medical, and Merit Medical.**



PUBLICATIONS AND PRESENTATIONS

LINKS IN TITLES

European Journal of Cancer:

- [Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial](#)
- [The Role of \[18F\]FES PET/CT in Breast Cancer Management: An Umbrella Review \(all EUBREAST Executive Board members participated\).](#)

European Journal of Surgical Oncology:

- [Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients – data from the prospective international AXSANA \(EUBREAST 3\) cohort study \(NCT04373655\)](#)

Breast Cancer Research and Treatment

- [Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer—a subgroup analysis of the prospective AXSANA](#)

ASCO

- Oral Presentation: [Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective](#)
- Poster Presentation: [MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions](#)

Swiss Conference of Gynecology and Obstetrics - third prize for abstract

- [Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy](#)

DGS Poster Presentation - AXSANA

EUBREAST NETWORK

August 2025

ONGOING EUBREAST PROJECTS

- **EUBREAST 1 (R) /GBG 104** concluded recruitment on 31 December 2024 with over 400 patients. The data follow-up is ongoing.
- **AXSANA/EUBREAST 3 (R)** recruited over 6600 patients between June 2020 and July 2025. It has continued as an unrestricted registry, **AXSANA Plus**. Results on two primary endpoints (axillary recurrence rate and life quality) are expected for this year. We thank all our collaborators for their remarkable support.
- **MELODY/EUBREAST 4** is the largest study worldwide on localization techniques for non-palpable breast cancer. 198 study sites are currently open in 23 countries. With more than 7000 patients enrolled, the study is progressing according to schedule.
- **SerMa/EUBREAST 5 (R)** After recruiting 50 patients, the study was put on hold to adapt the protocol and monitor the progress. We are currently writing an amendment and expect that recruitment will begin again soon.
- **I-PREPARE/EUBREAST 11 (R)** As of mid-July 2025, 473 patients were enrolled from 27 of the 30 active sites from 12 countries worldwide. Another 25 centers have received or are waiting for EC/final approval, and new centers have shown interest in joining. For info: goldman@eubreast.com
- **GRAMAREG/EUBREAST 15 (R)** is a non-interventional cohort study for patients with idiopathic granulomatous mastitis. The study has been approved by the Ethical Committee of the University of Lübeck, Germany. Currently, funding is being applied for.
- **UEMS-EUBREAST Breast Care Survey/EUBREAST 13 (R)** This study was conducted with The European Union of Medical Specialists (UEMS-Multidisciplinary Joint Committee Breast Care). We look forward to sharing the results soon.
- **Neo-ACT/EUBREAST 16 (R)** is a randomized study to examine if a physical exercise intervention during neoadjuvant chemotherapy for breast cancer (NACT) can increase pathological complete response rates (pCR rates) in breast cancer. The trial has now randomised about 280 patients in Finland, Sweden and Germany. Australia is initiated but they have not started enrolling patients yet. Scotland, Ireland, and New York (US) will open this autumn.
- **PROBAMUS/EUBREAST 18 (R)** This international registry has been launched with the aim of providing management paradigms for the occult primary breast cancer with axillary metastasis, a condition that is lagging behind in terms of evidence-based treatment and surgical de-escalation. Recruitment will start soon. For more information: marialuisa.gasparri@eoc.ch.
- **NAC-AX Delphi Consensus Study/EUBREAST 20 (R)** We are pleased to share that the international engagement in the first round has exceeded expectations, with 574 consultant breast surgeons taking part.

EUBREAST-SUPPORTED


- **PartBreCon-Pro**, a EUBREAST and ABS-supported international, prospective study of partial breast reconstruction using chest wall perforator flaps following breast-conserving surgery, has 700+ patients (2023-2028). For more information, contact partbrecon.pros@gmail.com

DIGITAL STRATEGY TEAM SUPERVISOR

We extend our heartfelt gratitude to **Dr. Eduard Bonci** for his dedication to supervising the EUBREAST social media platforms over the past two years. His invaluable support has been crucial to enhancing our online presence and fostering our network's growth. Edi will be shifting his focus to other areas of his career, so please join us in wishing him the best of luck in his future endeavors. We are happy to announce that he will continue to be a significant presence in our scientific community. *Stay tuned for details about the new Supervisor!*

I-BREAST BOOK WEBINAR

Thanks to **Yazan Massanat** and the **iBreastBook team** for the opportunity to present our studies. [Click here to watch the webinar](#) and learn more about our work.



I-PREPARE

LAUNCH MEETINGS

Special launch meetings were held for the **German and Italian Sites**. The [videos are available here](#). For more information about this study, please contact: goldman@eubreast.com



MILAN MARATHON 2026 CHARITY RUN

EUBREAST ETS is once again participating in the Milan Marathon Charity Run! If you are interested in running with us on **12 April 2026** in Milan or you would like to the support our runners and the I-PREPARE Study, please contact: info@eubreast.org

Special thanks to our super volunteer, Dr Monica Colombini, for her ongoing support.

